Uniseed is a venture capital firm founded in 2000 and based in Saint Lucia, Australia. Established as a joint initiative between the University of Melbourne and the University of Queensland, Uniseed focuses on investing in technology start-ups, particularly those emerging from its partner research organizations. The firm operates through multiple funds, with its latest, launched in 2015, involving the University of Sydney and CSIRO alongside its founding partners. Uniseed's investment strategy emphasizes long-term partnerships with academic institutions, providing tailored commercialization services that enhance their capabilities. The firm has made over 20 investments, typically ranging from $250,000 to $2.5 million, and has a track record of successful exits. Uniseed's commitment to supporting research commercialization is underscored by its significant contributions to the research ecosystem, which includes nearly $4 billion in research spending and numerous invention disclosures. The firm prioritizes a balanced approach to measuring success, focusing on financial returns, the establishment of viable start-ups, and the enhancement of commercialization processes for its partners.
A common conception is that motorcycling is dangerous. And to a certain extent, this is true. In contrast to modern cars, motorcycles lack standard safety equipment such as advanced driver warning and anti-collision systems. Forcite was borne to remedy and bridge this blatant gap: our helmet and software systems make motorcycling 10x safer. Sensor tech, the Forcite Command software platform and lightweight carbon fiber provide the basis for this disruptive technology. Take a look under the visor and learn more about what we have in store.
Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines. Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterial dissemination to the lungs.
Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines. Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterial dissemination to the lungs.
Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines. Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterial dissemination to the lungs.
Wildlife Drones has developed the world’s most innovative animal radio-tracking system using drones so you can track your radio-tagged animals like never before. With over 25 years experience undertaking ecological and scientific animal research, they understand the immense frustration when trying to track the movements of highly mobile animals. Receiving clear signals from radio-tagged animals can be difficult to achieve and is often a very labour intensive and expensive process. The main issue is height. When using hand-held radio-tracking from the ground, you often have to get the antenna as high as possible in order to improve signal detection. This often means finding higher ground, or even hiring helicopters or planes to get the slightest “ping” of a distant radio-tag. Unfortunately, it also often results in losing track of the precious animals you have worked so very hard to tag in order to understand their movements.
OccuRx, a Melbourne-based biopharmaceutical company, was established in 2014 with venture funding from the Medical Research Commercialisation Fund, Brandon Capital Partners and Uniseed. The Company’s primary focus is on the development of innovative therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis.
Morse Micro is a fast-growing wireless integrated circuit solutions company that is reinventing Wi-Fi for the Internet of Things (IoT). The company was founded by Wi-Fi pioneers and innovators, Michael De Nil and Andrew Terry, joined by the original Wi-Fi inventor Prof. Neil Weste and wireless industry veterans, whose teams designed Wi-Fi chips into billions of smartphones. Headquartered in Australia with offices in China and the U.S., Morse Micro’s strong and diverse system team, portfolio of IP and patents, enables Wi-Fi HaLow connectivity across the complete IoT ecosystem, from surveillance systems and access control to industrial automation and mobile devices, allowing connected devices to reach farther. www.morsemicro.com
Agerris is a field robotics and AI start-up for the agriculture industry, based on technology created at the Australian Centre for Field Robotics, the University of Sydney, where they have been developing air and ground robotic solutions for the agriculture industry since 2005.
A common conception is that motorcycling is dangerous. And to a certain extent, this is true. In contrast to modern cars, motorcycles lack standard safety equipment such as advanced driver warning and anti-collision systems. Forcite was borne to remedy and bridge this blatant gap: our helmet and software systems make motorcycling 10x safer. Sensor tech, the Forcite Command software platform and lightweight carbon fiber provide the basis for this disruptive technology. Take a look under the visor and learn more about what we have in store.
Wildlife Drones has developed the world’s most innovative animal radio-tracking system using drones so you can track your radio-tagged animals like never before. With over 25 years experience undertaking ecological and scientific animal research, they understand the immense frustration when trying to track the movements of highly mobile animals. Receiving clear signals from radio-tagged animals can be difficult to achieve and is often a very labour intensive and expensive process. The main issue is height. When using hand-held radio-tracking from the ground, you often have to get the antenna as high as possible in order to improve signal detection. This often means finding higher ground, or even hiring helicopters or planes to get the slightest “ping” of a distant radio-tag. Unfortunately, it also often results in losing track of the precious animals you have worked so very hard to tag in order to understand their movements.
PERKii delivers live and protected probiotics, in a refreshing water-based drink with a delicious splash of natural flavour. With only 26 calories and just one and a half teaspoons of sugar from apples, PERKii is leading the way in beverages. PERKii is the way you feel as your body responds to the goodness of live probiotics. As you discover the delicious taste of PERKii, we know your taste buds and your body will thank you. Microgels are tiny natural beads that encapsulate the probiotics in PERKii to ensure its survival through the acidic stomach environment, to the lower digestive system, where the probiotics actually do their work. The process of creating Microgels (Progel™ technology), on a commercial scale, was developed by scientists at The University of Queensland in Brisbane. No other probiotic drink can boast the use of this world-first technology. Progel™ technology allows the delivery of live and protected probiotics, in a refreshing drink, using 85% water with great natural flavours.
Exonate is a privately held, early stage, biotech company spun out of the University of Nottingham that is focused on alternative splicing of Vascular Endothelial Growth Factor (VEGF) in ophthalmology. Exonate’s lead programme is focused on Diabetic Macular Oedema (DMO). A consequence of diabetic retinopathy, DMO, is swelling in an area of the retina called the macula and wet Age-Related Macular Degeneration (wAMD), which is the leading cause of vision loss in people aged 60 and older. The Company is founded on scientific excellence with strong links to Professor David Bates and his lab at Nottingham University specializing in the biology and biochemical pathways of VEGF splice variants. Exonate have developed small molecules that inhibit production of pro-angiogenic VEGF through selective inhibition of serine/threonine-protein kinase 1 (SRPK1)-mediated VEGF splicing. These inhibitors have already demonstrated superior efficacy as topical agents in preclinical models of wet AMD. Through a Wellcome Trust funded project, Exonate has completed an optimization programme and has nominated a pre-clinical candidate drug with optimal characteristics. During the second quarter of 2020 regulatory toxicology and safety pharmacology studies have taken place. This is to support the successful application to the regulatory authorities for clinical evaluation. Exonate is led by an experienced, international management team that has previously worked together with cross-disciplinary experience in medicine and drug development, as well as successful fundraising for early stage companies. About Diabetic Macular Oedema (DMO)*: DMO is the build-up of fluid (Oedema) in a region of the retina called the macula. The macula is important for the sharp, straight-ahead vision that is used for reading, recognizing faces, and driving. DMO is the most common cause of vision loss among people with diabetic retinopathy. About half of all people with diabetic retinopathy will develop DMO and although it is more likely to occur as diabetic retinopathy worsens, DMO can happen at any stage of the disease. About wet Age-Related Macular Degeneration (wet AMD): Today, wet AMD is a leading cause of vision loss in people aged 60 years or older and affects more than 30 million patients worldwide, over 200,000 of those in the UK alone. If untreated patients are likely to lose sight in the affected eye within 24 months of disease onset. The main currently available treatment options for DMO and wet AMD are: • anti-VEGF antibody drugs – to prevent the growth of new blood vessels in the eye. Unlike small molecule drugs or eye drops these treatments must be injected into the eye once every 1 or 2 months. Resistance can develop to these drugs causing the disease to progress anew. • Laser surgery – to destroy abnormal blood vessels in the eye. This type of surgery is only suitable if blood vessel damage is not too extensive and if the abnormal blood vessels aren't close to the fovea, as performing surgery close to this part of the eye can cause permanent vision loss. • With DMO, Corticosteroids either injected or implanted into the eye, may be used alone or in combination with other drugs or laser surgery to treat DMO. *source: https://nei.nih.gov/health/diabetic/retinopathy
Q-Sera technology aims to accelerate the clotting of blood to more rapidly produce high quality serum in blood clotting tubes. Q-Sera Pty Ltd uses the coagulant properties of snake venom-derived proteins to develop blood collection tubes that rapidly produce high quality serum. Australian scientists have found a way to use components of snake venom to improve an essential clinical tool which will assist in optimising laboratory efficiency, clinical diagnosis and patient care. The venom of some snakes (including the Australian Taipan) has a potent ability to coagulate the blood of mammals including humans and it is this ability which caught the interest of a group of Queensland medical scientists and pathologists. The team isolated the potent clotting proteins and used them to develop superior blood collection tubes.
Kinoxis Therapeutics is an early stage biotechnology company based in Australia that is working to progress the development of a range of novel therapeutic compounds for the treatment of substance use disorders and other CNS conditions. The company has licensed these compounds from the University of Sydney, with the lead candidate demonstrating potent anti-addictive and prosocial effects in a number of different animal models and is progressing through pre-clinical testing.
Nexgen is an emerging plant trait company delivering non-GM solutions for a range of pathogens, production traits and consumer traits. Our solutions help agriculture-dependent communities around the world improve returns and respond rapidly to emerging opportunities and challenges. The proprietary transformation technique is developing crops that are virus-resistant; fungal-resistant; salt-tolerant; high in anthocyanin content; and aromatic. These solutions are developing the next generation of globally valued crops for food, fibre, energy and ornamentation.
Certa is an operational management platform that provides a fully integrated suite of products for third-party lifecycle management. The company's automated SaaS platform is used for business-to-business interactions, including on-boarding, due diligence, risk mitigation, and monitoring of third-party relationships.
Kinoxis Therapeutics is an early stage biotechnology company based in Australia that is working to progress the development of a range of novel therapeutic compounds for the treatment of substance use disorders and other CNS conditions. The company has licensed these compounds from the University of Sydney, with the lead candidate demonstrating potent anti-addictive and prosocial effects in a number of different animal models and is progressing through pre-clinical testing.
Cardihab provides a cloud-based portal to support traditional in-clinic programs and to facilitate remote cardiac rehabilitation using telephone support rather than clinic visits. As program content can be delivered via a smartphone app, patients need to only attend the clinic for their initial baseline assessment and final stage-discharge assessment, instead of multiple times a week for the duration of the program.
Brisbane Materials aims to be the leading supplier of anti-reflective and anti-soiling coatings for solar and other applications. Born out of the University of Queensland in 2005, Brisbane Materials builds on six years and significant investment in technology and application experience. Longer term, Brisbane Materials will extend its unique room temperature and atmospheric pressure synthesis of glass and ceramic coatings to a wide variety of materials systems and applications.
QUE Oncology, Inc. (QUE) was formed through a collaboration between Emory University, in Atlanta, Georgia, and The University of Queensland (UQ) research commercialization company, UniQuest, in Brisbane, Australia. QUE licenses intellectual property originating from research discoveries at both UQ and Emory’s Institute for Drug Development (EIDD). The leading drug candidate is Q-122, a compound with anti-inflammatory properties that is in Phase 1b clinical development for the treatment of hot flashes in women with breast cancer who are receiving anti-estrogen therapy. Additional cancer research projects that have been identified to supply the QUE Oncology pipeline are designed to address prostate cancer, breast cancer, melanoma, and cancer pain.
Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines. Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterial dissemination to the lungs.
Smart Sparrow owns and operates an e-learning platform, which enables students and professionals to create an e-learning courseware. It allows customers to create courseware on various subjects, including digital literacy, computer sciences, engineering, finance, marketing, medicine, orientation, sciences, and soft skills, as well as training courses. Smart Sparrow serves various institutions locally and internationally. Ariel Shoham, Dror Ben-Haim, Shaowei Ho, and Zack Belinson founded it on December 29, 2010, with its headquarters in Surry Hills in Australia with an additional office in San Francisco in California.
Exonate is a privately held, early stage, biotech company spun out of the University of Nottingham that is focused on alternative splicing of Vascular Endothelial Growth Factor (VEGF) in ophthalmology. Exonate’s lead programme is focused on Diabetic Macular Oedema (DMO). A consequence of diabetic retinopathy, DMO, is swelling in an area of the retina called the macula and wet Age-Related Macular Degeneration (wAMD), which is the leading cause of vision loss in people aged 60 and older. The Company is founded on scientific excellence with strong links to Professor David Bates and his lab at Nottingham University specializing in the biology and biochemical pathways of VEGF splice variants. Exonate have developed small molecules that inhibit production of pro-angiogenic VEGF through selective inhibition of serine/threonine-protein kinase 1 (SRPK1)-mediated VEGF splicing. These inhibitors have already demonstrated superior efficacy as topical agents in preclinical models of wet AMD. Through a Wellcome Trust funded project, Exonate has completed an optimization programme and has nominated a pre-clinical candidate drug with optimal characteristics. During the second quarter of 2020 regulatory toxicology and safety pharmacology studies have taken place. This is to support the successful application to the regulatory authorities for clinical evaluation. Exonate is led by an experienced, international management team that has previously worked together with cross-disciplinary experience in medicine and drug development, as well as successful fundraising for early stage companies. About Diabetic Macular Oedema (DMO)*: DMO is the build-up of fluid (Oedema) in a region of the retina called the macula. The macula is important for the sharp, straight-ahead vision that is used for reading, recognizing faces, and driving. DMO is the most common cause of vision loss among people with diabetic retinopathy. About half of all people with diabetic retinopathy will develop DMO and although it is more likely to occur as diabetic retinopathy worsens, DMO can happen at any stage of the disease. About wet Age-Related Macular Degeneration (wet AMD): Today, wet AMD is a leading cause of vision loss in people aged 60 years or older and affects more than 30 million patients worldwide, over 200,000 of those in the UK alone. If untreated patients are likely to lose sight in the affected eye within 24 months of disease onset. The main currently available treatment options for DMO and wet AMD are: • anti-VEGF antibody drugs – to prevent the growth of new blood vessels in the eye. Unlike small molecule drugs or eye drops these treatments must be injected into the eye once every 1 or 2 months. Resistance can develop to these drugs causing the disease to progress anew. • Laser surgery – to destroy abnormal blood vessels in the eye. This type of surgery is only suitable if blood vessel damage is not too extensive and if the abnormal blood vessels aren't close to the fovea, as performing surgery close to this part of the eye can cause permanent vision loss. • With DMO, Corticosteroids either injected or implanted into the eye, may be used alone or in combination with other drugs or laser surgery to treat DMO. *source: https://nei.nih.gov/health/diabetic/retinopathy
PERKii delivers live and protected probiotics, in a refreshing water-based drink with a delicious splash of natural flavour. With only 26 calories and just one and a half teaspoons of sugar from apples, PERKii is leading the way in beverages. PERKii is the way you feel as your body responds to the goodness of live probiotics. As you discover the delicious taste of PERKii, we know your taste buds and your body will thank you. Microgels are tiny natural beads that encapsulate the probiotics in PERKii to ensure its survival through the acidic stomach environment, to the lower digestive system, where the probiotics actually do their work. The process of creating Microgels (Progel™ technology), on a commercial scale, was developed by scientists at The University of Queensland in Brisbane. No other probiotic drink can boast the use of this world-first technology. Progel™ technology allows the delivery of live and protected probiotics, in a refreshing drink, using 85% water with great natural flavours.
OccuRx, a Melbourne-based biopharmaceutical company, was established in 2014 with venture funding from the Medical Research Commercialisation Fund, Brandon Capital Partners and Uniseed. The Company’s primary focus is on the development of innovative therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis.
ProGel is a start-up company from the University of Queensland commercialising a revolutionary method of encapsulating active ingredients for inclusion in foods, cosmetics or pharmaceuticals. In certain applications ProGel allows for the first time encapsulated high value additives small enough to remain undetectable by the consumer, whilst still being cost effective to the manufacturer of the ingredients. This technology can make dry and liquid stable microgels, with the initial product targets being functional foods such as probiotic drinks or yoghurts, or omega-3 fatty acid enhanced foods. Multi-billion dollar markets have grown around each of these additives, and importantly they are each growing at above 10% per year.
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
Hatchtech is an Australian company developing a locally developed proprietary technology platform that will enable the creation of a new generation of lowtoxicity pest control products. Specifically, the patented technology allows the complete blocking of pest species egg hatch through a novel mode of action. The technology has applicability for controlling ectoparasites and other egg laying pests of humans, animal, crops and the built environment.
Nexgen is an emerging plant trait company delivering non-GM solutions for a range of pathogens, production traits and consumer traits. Our solutions help agriculture-dependent communities around the world improve returns and respond rapidly to emerging opportunities and challenges. The proprietary transformation technique is developing crops that are virus-resistant; fungal-resistant; salt-tolerant; high in anthocyanin content; and aromatic. These solutions are developing the next generation of globally valued crops for food, fibre, energy and ornamentation.
Hydrexia is an Australian company that has successfully designed, built, and tested systems that stores hydrogen in solid form, based on a proprietary magnesium alloy.
Hatchtech is an Australian company developing a locally developed proprietary technology platform that will enable the creation of a new generation of lowtoxicity pest control products. Specifically, the patented technology allows the complete blocking of pest species egg hatch through a novel mode of action. The technology has applicability for controlling ectoparasites and other egg laying pests of humans, animal, crops and the built environment.
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
Smart Sparrow owns and operates an e-learning platform, which enables students and professionals to create an e-learning courseware. It allows customers to create courseware on various subjects, including digital literacy, computer sciences, engineering, finance, marketing, medicine, orientation, sciences, and soft skills, as well as training courses. Smart Sparrow serves various institutions locally and internationally. Ariel Shoham, Dror Ben-Haim, Shaowei Ho, and Zack Belinson founded it on December 29, 2010, with its headquarters in Surry Hills in Australia with an additional office in San Francisco in California.
Otifex Therapeutics Pty Ltd is an emerging Australian specialty pharmaceutical company developing a new treatment for the most common cause of acquired hearing loss in childhood, Otitis Media with Effusion (OME or “glue ear”). Treating OME often means surgically inserting “grommets” (tympanostomy tubes) to help return middle ear pressure to normal; there are currently no non-invasive alternatives. Otifex is developing a novel nasal spray to make it easier for the ears to ‘pop’, improving middle ear pressure and helping OME resolve naturally. Our product has the potential to be the first effective non-surgical treatment for OME.
Hatchtech is an Australian company developing a locally developed proprietary technology platform that will enable the creation of a new generation of lowtoxicity pest control products. Specifically, the patented technology allows the complete blocking of pest species egg hatch through a novel mode of action. The technology has applicability for controlling ectoparasites and other egg laying pests of humans, animal, crops and the built environment.
BT Imaging is the market leader for electrical-inspection equipment used in the manufacturing of silicon blocks, silicon solar wafers and silicon solar cells.
ProGel is a start-up company from the University of Queensland commercialising a revolutionary method of encapsulating active ingredients for inclusion in foods, cosmetics or pharmaceuticals. In certain applications ProGel allows for the first time encapsulated high value additives small enough to remain undetectable by the consumer, whilst still being cost effective to the manufacturer of the ingredients. This technology can make dry and liquid stable microgels, with the initial product targets being functional foods such as probiotic drinks or yoghurts, or omega-3 fatty acid enhanced foods. Multi-billion dollar markets have grown around each of these additives, and importantly they are each growing at above 10% per year.
Manjrasoft Pty. Ltd. commercializes the grid and cloud computing software technologies developed by the Grid Computing and Distributed Systems Laboratory. It provides Aneka, a development and management platform with rapid application development and workload distribution capabilities; Aneka for distributed 3D rendering using Autodesk Maya; Aneka for education and training; Aneka design explorer tool, which is used to build a solution to accelerate 3D rendering; and build, accelerate, and manage services. The company serves engineering, entertainment and gaming, life sciences, and finance markets. Manjrasoft Pty. Ltd. was founded in 2008 and is headquartered in Melbourne, Australia.
Verva Pharmaceuticals Ltd. (“Verva”) was formed in December, 2007 by consolidation of key diabetes assets, discovery technologies and targets resident in Autogen Research Ltd. (formerly the diabetes-focused subsidiary of ChemGenex Pharmaceuticals) with those of obesity drug development company Adipogen Pharmaceuticals Pty Ltd. The combined product portfolio, technologies and expertise provide a substantial opportunity for rapid clinical progress and growth in high-value markets with a significant unmet medical need. Verva operates in a completely virtual mode, managed by a CEO and Directors with extensive international product development and partnering experience. Verva’s founding research was undertaken at the Metabolic Research Unit of Deakin University in Geelong, Australia; a state-of-the-art facility providing access to key in vitro and in vivo models and capabilities. Verva has subsequently engaged expert scientists, clinicians, technical advisers and contract research organisations worldwide to implement the Company’s research and development strategy.
Fibrotech Therapeutics develops and offers novel drug candidates for the treatment of fibrosis in chronic conditions. It develops drugs for kidney diseases, diabetics, heart failure, pulmonary fibrosis, and arthritis. Founded in 2006, Fibrotech Therapeutics is based in Wonga Park, Australia.
BT Imaging is the market leader for electrical-inspection equipment used in the manufacturing of silicon blocks, silicon solar wafers and silicon solar cells.
Pepfactants has developed a new way to break apart industrial emulsions, including those found in oil & gas operations, environmental remediation and other manufacturing processes. The company has discovered a chemical additive for demulsify the emulsions, where the additive is cheaper than many alternatives, and withstands extreme levels of salt and other contaminants. The chemical is readily available today as it is used for other, unrelated applications.
Fultec Semiconductor operates as a circuit protection semiconductor company. It offers transient blocking device for the over-voltage and over-current protection of telecommunication and data communication systems. The company's products offer wide bandwidth circuit protection against lightning, power induction, power cross, and short circuit events. Its products have applications, such as telecom, datacom, sensors, automotive, and power distribution. The company was founded in 2001 and is headquartered in Mountain View, California. As of October 13, 2008, Fultec Semiconductor, Inc. operates as a subsidiary of Bourns, Inc.
OPAL Therapeutics
Series A in 2005
OPAL Therapeutics Pty Limited operates as an immunotherapy development company in Australia. It develops therapies for the treatment of human immunodeficiency virus, Hepatitis C, and chronic infection. OPAL Therapeutics Pty Limited was incorporated in 2005 and is based in Melbourne, Australia.
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
Hatchtech is an Australian company developing a locally developed proprietary technology platform that will enable the creation of a new generation of lowtoxicity pest control products. Specifically, the patented technology allows the complete blocking of pest species egg hatch through a novel mode of action. The technology has applicability for controlling ectoparasites and other egg laying pests of humans, animal, crops and the built environment.
QRxPharma is an Australian-based, commercial-stage specialty pharmaceutical company focused on the development and commercialization of new pain management and abuse prevention products Based on a development strategy that focuses on enhancing the clinical utility of currently approved compounds as well as bringing new products to market, the company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes. In Q4 2013, the Company plans to refile with the US Food and Drug Administration a New Drug Application for its lead product candidate, immediate release MOXDUO®, for the treatment of acute pain. QRxPharma has entered into strategic agreements with Actavis Inc., Paladin Labs Inc. and Aspen Group for the commercialisation of immediate release MOXDUO in the US, Canada, Australia (including New Zealand and Oceania) and South Africa. The Company's clinical pipeline includes an intravenous (IV) and controlled release (CR) formulation of MOXDUO. QRxPharma is also collaborating with Aesica Formulation Development Limited, for the worldwide promotion of QRxPharma's proprietary Stealth Beadlets™ abuse deterrence technology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.